Basal Cell Carcinoma with a Relationship in Dermatology and Plastic Surgery
Main Article Content
Abstract
Skin cancers known as basal cell carcinomas (BCCs) can cause significant localized damage. They represent the most prevalent kind of cancer in the West. A lifetime incidence of up to 39% is possible. The most prevalent risk factor is UV exposure. Most of these tumors are seen in the head and neck region. Even though BCCs are often benign, the great occurrence of these conditions implies that treating them adds significantly to the health service's already heavy workload. It's critical to have a solid grasp of your potential possibilities. A number of variables, such as the patient's age and comorbidities, the location and subtype of the lesion, and others, may affect management choices. Treatment choices for BCCs on the face may differ greatly from those for BCCs originating elsewhere due to the significance of a favorable cosmetic and curative result. Good randomized controlled studies comparing different treatment methods are hard to come by. While conventional excision has historically been the preferred course of treatment, there are now a number of other alternatives as well, including as radiation, cryosurgery, curettage and cautery, Mohs micrographic surgery, topical imiquimod, photodynamic therapy, and topical 5-fluorouracil. We go over and evaluate the research and literature supporting the current range of face BCC treatment options.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Krakowski, A. C., Hafeez, F., Westheim, A., Pan, E. Y., & Wilson, M. (2022). Advanced basal cell carcinoma: What dermatologists need to know about diagnosis. Journal of the American Academy of Dermatology, 86(6), S1-S13.
II. Verkouteren, J. A. C., Ramdas, K. H. R., Wakkee, M., & Nijsten, T. (2017). Epidemiology of basal cell carcinoma: scholarly review. British Journal of Dermatology, 177(2), 359-372.
III. Chinem, V. P., & Miot, H. A. (2011). Epidemiology of basal cell carcinoma. Anais brasileiros de dermatologia, 86, 292-305.
IV. Lear, W., Dahlke, E., & Murray, C. A. (2007). Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. Journal of cutaneous medicine and surgery, 11(1), 19-30.
V. Peris, K., Fargnoli, M. C., Garbe, C., Kaufmann, R., Bastholt, L., Seguin, N. B., ... & European Association of Dermato-Oncology (EADO. (2019). Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines. European Journal of cancer, 118, 10-34.
VI. Sharquie, K. E., & Noaimi, A. A. (2012). Basal cell carcinoma: Topical therapy versus surgical treatment. Journal of the Saudi Society of Dermatology & Dermatologic Surgery, 16(2), 41-51.
VII. Bichakjian, C., Armstrong, A., Baum, C., Bordeaux, J. S., Brown, M., Busam, K. J., ... & Rodgers, P. (2018). Guidelines of care for the management of basal cell carcinoma. Journal of the American Academy of Dermatology, 78(3), 540-559.
VIII. Smith, V., & Walton, S. (2011). Treatment of facial basal cell carcinoma: a review. Journal of skin cancer, 2011.
IX. Beutner, K. R., Geisse, J. K., Helman, D., Fox, T. L., Ginkeld, A., & Owens, M. L. (1999). Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. Journal of the American Academy of Dermatology, 41(6), 1002-1007.
X. Oldfield, V., Keating, G. M., & Perry, C. M. (2005). Imiquimod: in superficial basal cell carcinoma. American journal of clinical dermatology, 6, 195-200.
XI. Raasch, B. (2009). Management of superficial basal cell carcinoma: focus on imiquimod. Clinical, Cosmetic and Investigational Dermatology, 65-75.
XII. Savoia, P., Deboli, T., Previgliano, A., & Broganelli, P. (2015). Usefulness of photodynamic therapy as a possible therapeutic alternative in the treatment of basal cell carcinoma. International journal of molecular sciences, 16(10), 23300-23317.
XIII. Wang, H., Xu, Y., Shi, J., Gao, X., & Geng, L. (2015). Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta‐analysis. Photodermatology, photoimmunology & photomedicine, 31(1), 44-53.
XIV. Franco, R., Anniciello, A. M., Botti, G., Caraglia, M., & Luce, A. (2013). Basal Cell Carcinoma: Molecular and Pathological Features. In Skin Cancer: A Practical Approach (pp. 75-88). New York, NY: Springer New York.
XV. Kuijpers, D. I., Thissen, M. R., & Neumann, M. H. (2002). Basal cell carcinoma: treatment options and prognosis, a scientific approach to a common malignancy. American journal of clinical dermatology, 3, 247-259.
XVI. Walker, P., & Hill, D. (2006). Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australasian Journal of Dermatology, 47(1), 1-12.
XVII. Shriner, D. L., McCoy, D. K., Goldberg, D. J., & Wagner Jr, R. F. (1998). Mohs micrographic surgery. Journal of the American Academy of Dermatology, 39(1), 79-97.
XVIII. Delgado Jiménez, Y., Camarero‐Mulas, C., Sanmartín‐Jiménez, O., Garcés, J. R., Rodríguez‐Prieto, M. Ã., Alonso‐Alonso, T., ... & REGESMOHS. (2018). Differences of Mohs micrographic surgery in basal cell carcinoma versus squamous cell carcinoma. International Journal of Dermatology, 57(11), 1375-1381.
XIX. Fania, L., Didona, D., Morese, R., Campana, I., Coco, V., Di Pietro, F. R., ... & Dellambra, E. (2020). Basal cell carcinoma: from pathophysiology to novel therapeutic approaches. Biomedicines, 8(11), 449.